Thyroid and Fertility: TSH, T3, T4 in the Workup

Your TSH came back inside the lab reference range, but you have read that fertility targets are tighter, that something called subclinical hypothyroidism is a thing, and that thyroid antibodies are tied to miscarriage. You want to know which thyroid numbers actually matter for conception, what the preconception target is, and whether to push for treatment now or wait.

Among the labs for fertility workup, thyroid testing is one of the highest-yield, lowest-cost steps we run. Thyroid disease is also one of the few causes of subfertility and recurrent loss that we can correct cleanly: once dosed properly, the obstacle is gone. The trade-off is that thyroid numbers are easy to misinterpret, and the gap between "lab-normal" and "preconception-optimal" trips up patients and primary care clinicians alike.

Why the thyroid matters for fertility

Thyroid hormone is required for normal function of the hypothalamic-pituitary-ovarian axis. When thyroid hormone is too low or too high, the conversation between the brain and the ovaries gets noisy. Both overt and subclinical thyroid disease are associated with ovulatory dysfunction, menstrual irregularity, infertility, miscarriage, preterm birth, and adverse neurodevelopmental outcomes in the child.¹,⁵

The clinical picture I see most often is subclinical hypothyroidism, where TSH is elevated but free T4 is still in range, in a person with irregular cycles or recurrent early loss. Less commonly, I see overt hypothyroidism that has been missed in primary care, or hyperthyroidism presenting with secondary amenorrhea.

Anti-thyroid peroxidase (TPO) antibodies deserve their own mention. Even when TSH is in the standard reference range, TPO antibody positivity independently raises miscarriage risk and predicts progression to overt hypothyroidism during pregnancy.¹ This is why many specialists check antibodies in a person with recurrent loss or unexplained subfertility, even when TSH looks fine.

Where thyroid sits in the labs for fertility workup

The thyroid component of a fertility workup is small and standard.

• TSH is the screening test. The pituitary's TSH output is exquisitely sensitive to thyroid hormone levels, which makes a normal TSH a strong indicator that thyroid function is intact at the moment of the draw.
• Free T4 reflects circulating thyroid hormone. It is needed whenever TSH is abnormal, and at least once at baseline if you are working up subfertility.
• Free T3 is rarely required in a fertility evaluation. It is useful in suspected T3 toxicosis and in some specific endocrine settings, but in routine fertility workups it does not add much.
• TPO antibodies (anti-thyroid peroxidase) flag autoimmune thyroid disease. Worth checking even when TSH is in range, particularly in recurrent miscarriage workup and in PCOS.
• TgAb (anti-thyroglobulin) is occasionally added to a thyroid autoimmune panel.
• Reverse T3 is not recommended in routine fertility workup, despite popular online advice. The science does not support its use as a fertility marker.

If you are looking at a private blood draw and seeing an fsh lh prolactin tsh test offered together, that is the panel I would also expect to see on a fertility-aware general practice request. It is reasonable.

The numbers that matter

The reference ranges differ by lab and assay, but the rough landscape is consistent.

The general-population TSH reference is roughly 0.4 to 4.5 mIU/L. The preconception and pregnancy thresholds are tighter. Current ATA 2017 and ASRM guidance support a preconception TSH target around 0.5 to 2.5 mIU/L for people trying to conceive, particularly when TPO antibodies are positive or there is a history of recurrent loss.¹,² The European Thyroid Association 2021 guideline on assisted reproduction takes a similar position.³

In pregnancy itself, free T4 must be interpreted against trimester-specific reference ranges. The non-pregnant normal range does not apply to a pregnant person, and labs that report non-pregnant ranges for pregnant samples can mislead.

What this means in practice:

• A TSH between 2.5 and 4.5 mIU/L looks "normal" on a generic report but sits in a grey zone for someone trying to conceive. The grey zone matters most if TPO antibodies are positive or if there is a history of miscarriage.
• A TPO-positive person with TSH above 2.5 mIU/L is a common scenario in which I would either initiate or titrate levothyroxine.
• A frankly elevated TSH with a low free T4 is overt hypothyroidism, and treatment is not optional before active TTC.

The patterns and what they mean

The same five thyroid patterns come up over and over.

Overt hypothyroidism: TSH high, free T4 low. Treat with levothyroxine. Do not delay conception efforts beyond reaching target, but do reach target before starting medicated cycles.

Subclinical hypothyroidism: TSH high, free T4 normal. Treatment threshold is debated. The ATA 2017 guideline recommends treating subclinical hypothyroidism in pregnancy when TSH is above 4.0 mIU/L, and considering treatment when TPO antibody is positive at lower TSH values.¹ The ASRM committee opinion is slightly more conservative but supports treatment when TSH exceeds the preconception target and TPO positivity is present.² I tend to treat when TSH is above 2.5 mIU/L with TPO positivity, or above 4.0 mIU/L without.

Euthyroid, TPO antibody positive: monitor TSH every four to six weeks during early pregnancy. Some specialists treat preemptively in the recurrent miscarriage population.

Overt hyperthyroidism: TSH low, free T4 high. This needs endocrine evaluation before conception. Treatment options (anti-thyroid drugs, radioactive iodine, surgery) have different implications for fertility timing.

Subclinical hyperthyroidism: TSH low, free T4 normal. Check that thyroid replacement is not being over-dosed. Exclude early pregnancy itself, where the hCG surge can suppress TSH in the first trimester.

Why "your TSH is normal" is sometimes not enough

This is the conversation I have most often. Someone comes in with a TSH of 3.8, told by primary care that thyroid is fine, and we are trying to figure out why cycles are irregular or why there have been three early losses.

A few things to hold together.

The lab's reference range is built from a general population that includes a meaningful number of people with undiagnosed thyroid disease, which inflates the upper end of "normal." Fertility-specific ranges are tighter for exactly this reason.

TSH is also biologically variable, fluctuating up to 20 to 30 percent day to day in the same person. So a single mildly elevated TSH should be repeated before major decisions, ideally in four to six weeks, at the same time of day, off any recent dose change.

After a levothyroxine dose change, retest at six weeks. The half-life of levothyroxine is around seven days, and the body's set point takes about five half-lives to stabilise. Earlier values can mislead.

Dosing and timing notes for levothyroxine

I want to be careful here: I am giving general information, not personalised dose advice. Your prescriber sets your dose.

Levothyroxine is taken in the morning, on an empty stomach, with water, ideally 30 to 60 minutes before food. Coffee, calcium supplements, iron supplements, and proton pump inhibitors should be separated from the dose by at least four hours, ideally longer, because they impair absorption.

Pregnancy increases thyroid hormone requirement by roughly 20 to 30 percent in the first trimester. Once a pregnancy test is positive, contact your prescriber promptly. Most patients on levothyroxine pre-pregnancy will need a dose increase by the time of the first beta-hCG.¹

Preconception optimisation, in practice, means a stable TSH below 2.5 mIU/L for at least one full cycle before active conception attempts, in a TPO-positive or recurrent-loss patient. In someone without those features, the bar can be slightly higher, but I aim for the same target.

Iodine sufficiency matters, especially in regions where dietary iodine is low. The flip side is that iodine excess from over-the-counter kelp or iodine supplements can worsen autoimmune thyroid disease. A standard prenatal vitamin contains a safe amount; standalone iodine supplements should be discussed with your clinician.

Thyroid and PCOS

The PCOS and thyroid overlap matters more than most people are told.

Hypothyroidism can mimic PCOS. Anovulation, irregular cycles, mildly raised androgens, and even some weight changes can all be driven by an undertreated thyroid. Current PCOS guidelines are explicit: TSH should be checked before applying Rotterdam criteria, because a thyroid abnormality must be excluded as the cause of the menstrual disturbance first. If you are reading how PCOS is diagnosed by Rotterdam criteria, the thyroid step sits at the front of that pathway.

PCOS and Hashimoto's also co-occur more often than chance alone would predict. Checking TPO antibodies as part of the PCOS blood test panel is reasonable, and I do it routinely. Treating coexisting hypothyroidism does not "cure" PCOS. It removes one confounder, which can simplify the picture and sometimes restore more regular ovulation on its own.

Thyroid in the male partner

Severe thyroid disease in the male partner can affect spermatogenesis, particularly sperm concentration and motility. Routine TSH screening of the male partner is not part of a standard workup, but a TSH is a reasonable add-on when there is unexplained infertility, recurrent loss, or symptoms suggestive of thyroid disease in him. The yield is low but the test is cheap.

What to ask at the appointment

The conversation goes faster if you arrive with a short list:

1. What is my current TSH, free T4, and TPO antibody status?
2. What is the preconception TSH target for someone in my situation?
3. If I am in subclinical territory, what is the specific case for or against treatment in my case?
4. If I start or adjust levothyroxine, when do we retest?
5. What dose change should I anticipate when I get a positive pregnancy test, and who do I call?

If your clinician's answers are vague or you are being told repeatedly that "your TSH is normal" without engagement with the antibody status or your recurrent-loss history, that is a reasonable trigger for a second look. The supporting post on when to get a second opinion covers how to do that without burning the bridge.

What's next

• For the rest of the hormonal panel: AMH, FSH, LH explained and the PCOS blood test panel
• For the PCOS overlap: how PCOS is diagnosed by Rotterdam criteria
• For prolactin (often checked alongside thyroid): prolactin and fertility
• If thyroid sits in a recurrent-loss workup: recurrent loss workup tests

Sources

1. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017;27(3):315–389. https://doi.org/10.1089/thy.2016.0457
2. Practice Committee of the American Society for Reproductive Medicine. Subclinical hypothyroidism in the infertile female population: a guideline. Fertility and Sterility 2015;104(3):545–553. https://doi.org/10.1016/j.fertnstert.2015.05.028
3. Poppe K, Bisschop P, Fugazzola L, Minziori G, Unuane D, Weghofer A. 2021 European Thyroid Association Guideline on Thyroid Disorders prior to and during Assisted Reproduction. European Thyroid Journal 2021;9(6):281–295. https://doi.org/10.1159/000512790
4. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertility and Sterility 2012;98(5):1103–1111. https://doi.org/10.1016/j.fertnstert.2012.06.048
5. Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nature Reviews Endocrinology 2017;13(10):610–622. https://doi.org/10.1038/nrendo.2017.93
6. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767–793. https://doi.org/10.1016/j.fertnstert.2023.07.025